View Archive »
About The Cover
The October cover of Oncotarget depicts a phenotype of zebrafish injected with CIC MO. The knock-down of CIC results in mitochondrial DNA depletion and activation of autophagy. See Catalina-Rodriguez et al.
|
|
Table of Contents
Editorial
|
| Targeting SHP2 phosphatase in Myeloproliferative Neoplasms |
|
https://doi.org/10.18632/oncotarget.665
|
| 1049-1051 |
|
| p53 as a target in myeloproliferative neoplasms |
|
https://doi.org/10.18632/oncotarget.719
|
| 1052-1053 |
|
| Inhibiting the molecular evolution of cancer through HSP90 |
|
https://doi.org/10.18632/oncotarget.738
|
| 1054-1056 |
|
| Regulation of the p53 by Helicobacter pylori |
|
https://doi.org/10.18632/oncotarget.698
|
| 1057-1058 |
|
| HLX in AML: novel prognostic and therapeutic target |
|
https://doi.org/10.18632/oncotarget.705
|
| 1059-1060 |
|
| Exploiting the mTOR paradox for disease prevention |
|
https://doi.org/10.18632/oncotarget.712
|
| 1061-1063 |
|
| Too much AKT turns PAX3FKHR dead: A prospect of novel therapeutic strategy for alveolar rhabdomyosarcoma |
|
https://doi.org/10.18632/oncotarget.713
|
| 1064-1065 |
|
| Burkitt lymphomagenesis linked to MYC plus PI3K in germinal center B cells |
|
https://doi.org/10.18632/oncotarget.726
|
| 1066-1067 |
Reviews
|
| Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance |
|
https://doi.org/10.18632/oncotarget.659
|
| 1068-1111 |
Research: Complementary Reports
|
| Disulfiram a drug widely used to control alcoholism suppresses the selfrenewal of glioblastoma and overrides resistance to temozolomide |
|
https://doi.org/10.18632/oncotarget.604
|
| 1112-1123 |
|
| HighThroughput Chemical Screens Identify Disulfiram as an Inhibitor of Human Glioblastoma Stem Cells |
|
https://doi.org/10.18632/oncotarget.707
|
| 1124-1136 |
Research Papers
|
| High cytidine deaminase expression in the liver provides sanctuary for cancer cells from decitabine treatment effects |
|
https://doi.org/10.18632/oncotarget.597
|
| 1137-1145 |
|
| FOXP3 a novel glioblastoma oncosuppressor affects proliferation and migration |
|
https://doi.org/10.18632/oncotarget.644
|
| 1146-1157 |
|
| Heat Shock Protein 90 is overexpressed in highrisk myelodysplastic syndromes and associated with higher expression and activation of Focal Adhesion Kinase |
|
https://doi.org/10.18632/oncotarget.557
|
| 1158-1168 |
|
| Targeting JNKinteractingprotein1 JIP1 sensitises osteosarcoma to doxorubicin |
|
https://doi.org/10.18632/oncotarget.600
|
| 1169-1181 |
|
| Upregulation of cMYC and SIRT1 expression correlates with malignant transformation in the serrated route to colorectal cancer |
|
https://doi.org/10.18632/oncotarget.628
|
| 1182-1193 |
|
| Wholeexome sequencing identifies ATRX mutation as a key molecular determinant in lowergrade glioma |
|
https://doi.org/10.18632/oncotarget.689
|
| 1194-1203 |
|
| Reactivation of codogenic endogenous retroviral ERV envelope genes in human endometrial carcinoma and prestages: Emergence of new molecular targets |
|
https://doi.org/10.18632/oncotarget.679
|
| 1204-1219 |
|
| The mitochondrial citrate transporter CIC is essential for mitochondrial homeostasis |
|
https://doi.org/10.18632/oncotarget.714
|
| 1220-1235 |
|
| Effects of Ectopic Expression of NGAL on Doxorubicin Sensitivity |
|
https://doi.org/10.18632/oncotarget.691
|
| 1236-1245 |
|
| DNAdemethylating and antitumor activity of synthetic miR29b mimics in multiple myeloma |
|
https://doi.org/10.18632/oncotarget.675
|
| 1246-1258 |
Copyright © 2026 Rapamycin Press LLC dba Impact Journals
Oncotarget ® is a registered trademark of Rapamycin Press LLC
Impact Journals ® is a registered trademark of Rapamycin Press LLC
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLC
